{"Clinical Trial ID": "NCT01712009", "Intervention": ["INTERVENTION 1:", "No prophylaxis", "Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim.", "INTERVENTION 2:", "Naproxene 500 mg twice daily", "Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim in addition to prophylactic naproxen 500 mg orally twice daily (BID) for 5 days in each of the 4 cycles, starting on the day of pegfilgrastim administration."], "Eligibility": ["\u2022 Aged 18 or over", "- Performance Status of the Eastern Cooperative Oncology Group (ECOG) 0-2", "Newly diagnosed women, not previously treated with chemotherapy, breast cancer stage I-III", "Medically eligible to safely receive adjuvant or neoadjuvant chemotherapy, pegfilgrastim, naproxene and loratadine, as determined by the investigator", "Creatinine 1.5 X upper limit of normal (ULN)", "Consider receiving at least 4 cycles of adjuvant or neoadjuvant chemotherapy", "Consider receiving pegfilgrastim prophylaxis from the first cycle and continue throughout each chemotherapy cycle of the treatment period", "The subject gave his informed consent", "\u2022 Exclusion criteria", "History of other malignities over the past five years, with the exception of the following:", "Non-melanoma skin cancer or lentigo maligna properly treated without signs of disease", "\u2022 Cervical carcinoma properly treated in situ without signs of disease", "Consider receiving weekly chemotherapy", "\u25cf Continuous chronic pain or other painful conditions requiring treatment (including immediate post-operative treatment of surgical pain or pain associated with the procedure) as determined by the investigator", "Premedication related to the administration of chemotherapy, and the use of anti-emetics is permitted, according to usual clinical practice", "- Chronic use of oral nonsteroidal anti-inflammatory drugs (NSAIDs) or oral antihistamines other than those dictated by the randomization groups described in the protocol, with the exception of:", "- Chronic oral aspirin for cardiovascular indications", "\u2022 Prior chemotherapy treatment for cancer within 5 years of the current diagnosis of breast cancer", "Prior use of granulocyte colony stimulating factor (G-CSF)", "\u2022 History of clinically significant gastrointestinal (GI) bleeding, history of gastrointestinal ulcers or active gastrointestinal bleeding within 6 months prior to randomization", "History of clinically significant haemorrhagic disorders, thromboembolism within 6 months prior to randomization", "Currently enrolled in, or less than 30 days from the end of, another clinical trial that includes the leading language G-CSF (filgrastim, pegfilgrastim, other) or granulocytes-macrophagus colony stimulation factor (GM-CSF) (sargramostim)", "At present, or less than 30 days after the end of the trial, another interventional clinical trial including blinded treatment or blinded treatment arm (whether randomized to blinded or blinded arm)", "At present, or less than 30 days after the end of the study, another interventional clinical trial involving the use of an agent that is not currently considered a standard treatment for the adjuvant or neoadjuvant treatment of Stage I-III breast cancer, based on the National Comprehensive Cancer Network (NCCN) Oncology Clinical Practice Guidelines for Breast Cancer", "Currently enrolled in, or less than 30 days from the end of, any pain intervention study", "\u2022 Pregnant, lactating or reproductively potential women who are not willing to use an effective birth control method during treatment and for 17 days after discontinuation of study therapy", "A history or evidence of any other clinically significant disorder, condition or disease (except those described above) that, in the opinion of the investigator or the Amgen, if consulted, would pose a safety risk or interfere with the assessment, procedures or completion of the study."], "Results": ["Performance measures:", "Percentage of participants with bone pain (all classes) in Cycle 1", "The bone pain data were entered as part of the Standard Adverse Reaction Reporting (AR).", "Duration: Cycle 1 (approximately 4 weeks, depending on the chemotherapy treatment interval)", "Results 1:", "Title of arm/group: No prophylaxis", "Description of the arm/group: Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim.", "Total number of participants analysed: 191", "Type of measurement: Number", "Unit of measure: percentage of participants 46.6 (39.4 to 53.9)", "Results 2:", "Title of the arm/group: Naproxen 500 mg BID", "Description of the arm/group: Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim in addition to prophylactic naproxen 500 mg orally twice daily (BID) for 5 days in each of the 4 cycles, starting on the day of pegfilgrastim administration.", "Total number of participants analysed: 196", "Type of measurement: Number", "Unit of measure: percentage of participants 40.3 (33.4 to 47.5)"], "Adverse Events": ["Undesirable Events 1:", "Total: 34/196 (17.35 per cent)", "Anemia 1/196 (0.51%)", "7/196 (3.57%)", "Neutropenia 2/196 (1.02%)", "Pancytopenia 1/196 (0.51%)", "Angina pectoris 1/196 (0.51%)", "Atrial fibrillation 0/196 (0.00 %)", "Congestive heart failure 0/196 (0.00 %)", "Pericarditis 1/196 (0.51%)", "Colite 2/196 (1.02%)", "Ischaemic colitis 1/196 (0.51%)", "Constipation 0/196 (0.00 %)", "Adverse Events 2:", "Total: 30/193 (15.54 per cent)", "Anemia 1/193 (0.52%)", "Febrile neutropenia 6/193 (3.11%)", "Neutropenia 0/193 (0.00 %)", "Pancytopenia 0/193 (0.00 %)", "Angine pectoris 0/193 (0.00 %)", "Atrial fibrillation 1/193 (0.52%)", "Congestive heart failure 1/193 (0.52%)", "Pericarditis 0/193 (0.00 %)", "- Colitis 1/193 (0.52%)", "Ischemic colitis 0/193 (0.00 %)", "Constipation 1/193 (0.52%)"]}